ZYNERBA PHARMACEUTICALS INC (ZYNE)
US98986X1090 - Common Stock
Overall ZYNE gets a fundamental rating of 2 out of 10. We evaluated ZYNE against 198 industry peers in the Pharmaceuticals industry. The financial health of ZYNE is average, but there are quite some concerns on its profitability. ZYNE has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year ZYNE has reported negative net income.
ZYNE had a negative operating cash flow in the past year.
ZYNE had negative earnings in each of the past 5 years.
ZYNE had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ZYNE's Return On Assets of -92.85% is on the low side compared to the rest of the industry. ZYNE is outperformed by 78.47% of its industry peers.
ZYNE has a worse Return On Equity (-129.50%) than 67.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -92.85% | ||
| ROE | -129.5% | ||
| ROIC | N/A |
ROA(3y)-59.46%
ROA(5y)-55.04%
ROE(3y)-71.26%
ROE(5y)-65.33%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ZYNE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, ZYNE has more shares outstanding
The number of shares outstanding for ZYNE has been increased compared to 5 years ago.
ZYNE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ZYNE has an Altman-Z score of -8.88. This is a bad value and indicates that ZYNE is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.88, ZYNE is doing worse than 74.64% of the companies in the same industry.
ZYNE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.88 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
ZYNE has a Current Ratio of 3.43. This indicates that ZYNE is financially healthy and has no problem in meeting its short term obligations.
ZYNE has a Current ratio of 3.43. This is comparable to the rest of the industry: ZYNE outperforms 49.76% of its industry peers.
A Quick Ratio of 3.43 indicates that ZYNE has no problem at all paying its short term obligations.
With a Quick ratio value of 3.43, ZYNE perfoms like the industry average, outperforming 52.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.43 | ||
| Quick Ratio | 3.43 |
3. Growth
3.1 Past
ZYNE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.98%, which is quite good.
EPS 1Y (TTM)13.98%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q12.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
ZYNE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.48% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-2.82%
EPS Next 2Y10.85%
EPS Next 3Y15.71%
EPS Next 5Y31.48%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ZYNE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZYNE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ZYNE's earnings are expected to grow with 15.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.85%
EPS Next 3Y15.71%
5. Dividend
5.1 Amount
ZYNE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ZYNERBA PHARMACEUTICALS INC
NASDAQ:ZYNE (10/10/2023, 7:00:03 PM)
After market: 1.3015 +0 (+0.12%)1.3
+0.03 (+2.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap70.12M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -92.85% | ||
| ROE | -129.5% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.43 | ||
| Quick Ratio | 3.43 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)13.98%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-2.82%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y